Invega Trinza

Invega Trinza

paliperidone

Manufacturer:

Janssen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Paliperidone palmitate
Indications/Uses
3-mth inj for maintenance treatment of schizophrenia in adults who have been adequately treated w/ 1-mth paliperidone palmitate inj for at least 4 mth.
Dosage/Direction for Use
IM Inj once every 3 mth, may be adjusted every 3 mth in increments of 175-525 mg based on tolerability &/or efficacy. Mild renal impairment Max recommended dose: 350 mg.
Contraindications
Hypersensitivity to paliperidone or risperidone.
Special Precautions
Not to be inj intravascularly, SC or in divided doses. Discontinue use if hypersensitivity reactions, tardive dyskinesia, extrapyramidal symptoms, severe neutropoenia occur. Not to be used in dementia-related psychosis; if neuroleptic malignant syndrome, clinically significant QT prolongation & drug‐induced leukopoenia/neutropoenia occur. Avoid use in congenital long QT syndrome, history of cardiac arrhythmias. Known CV or cerebrovascular disease, conditions predisposing to hypotension; Parkinson's disease, dementia w/ Lewy bodies; history of seizures or conditions lowering seizure threshold; dysphagia; psychotic illnesses; history of clinically significant low WBC; risk of factors for venous thromboembolism; priapism; body temp regulation; hyperglycaemia & DM; wt gain. Intraoperative floppy iris syndrome. Antiemetic effect. Avoid use in combination w/ class IA or III antiarrhythmics, antipsychotics, antibiotics or drugs prolonging QT interval; alcohol. Concomitant use w/ risperidone; psychostimulants eg, methylphenidate. Avoid inadvertent inj into blood vessel. May affect ability to drive & operate machines. Not recommended in moderate or severe renal impairment. Hepatic impairment. Pregnancy. Not to be used during lactation. Not recommended in paed <18 yr. Elderly w/ dementia.
Adverse Reactions
Anxiety, insomnia; nasopharyngitis, upper resp tract infection; increased wt; headache, akathisia; cough; inj site pain & induration; hyperglycaemia. Parkinsonism, sedation/somnolence, tremor; tachycardia; nausea; increased transaminases; musculoskeletal & back pain; amenorrhea, menstrual disorder.
Drug Interactions
Increased bloodstream conc w/ risperidone. Emergence of extrapyramidal symptoms w/ psychostimulants eg, methylphenidate. Antagonized effect of l-dopa & other dopamine agonists. Additive effect w/ orthostatic hypotension-inducing drugs. Decreased mean steady-state Cmax & AUC w/ carbamazepine. Increased Cmax & AUC w/ divalproex Na. Drugs prolonging QT interval; other centrally-acting drugs; alcohol.
MIMS Class
ATC Classification
N05AX13 - paliperidone ; Belongs to the class of other antipsychotics.
Presentation/Packing
Form
Invega Trinza PR susp for inj 350 mg/1.75 mL
Packing/Price
1's
Form
Invega Trinza PR susp for inj 263 mg/1.315 mL
Packing/Price
1's
Form
Invega Trinza PR susp for inj 525 mg/2.625 mL
Packing/Price
1's
Form
Invega Trinza PR susp for inj 175 mg/0.875 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in